Abstract 18083: Drug-Eluting Stents With Cobalt-Chromium Platforms Reduce Myocardial Infarction Rate At 30 Days. A Meta-Analysis Of 9 Randomized Clinical Trials.
Introduction: After the widespread entry of drug-eluting stents (DES) to PCI, the risk of restenosis was strikingly reduced. Most of the ischemic complications like myocardial infarction (MI) occur now as a complication of the procedure itself. Cobalt-chromium (CC) platforms allow stents to have thinner struts and thus better flexibility and deliverability. We assessed the hypothesis that DES-CC would have a lower rate of early MI after PCI compared to older stainless steel (SS) stents.
Methods: We performed a meta-analysis of 9 randomized clinical trials with information about MI rate at 30 days, and that compared CC-DES to SS-DES. A total of 10.970 patients were included.
Results: CC-DES had a lower rate of MI at 30 days compared to SS-DES (2.3% vs. 3.9%, respectively; p = 0.006; OR 0.72; 95%CI 0.58 – 0.91). This means a relative reduction of 41% and a NNT of 62 patients to prevent one MI.
Conclusions: PCI with CC-DES may offer a clinical benefit compared to SS-DES due to a significant reduction in the rate of myocardial infarction at 30 days after PCI.
- © 2010 by American Heart Association, Inc.